Andrographis recalls: Concerns over allergy risk

Consumers are advised that the medicines listed below containing Andrographis are being recalled by sponsors.

Why this is happening

Listed medicines are generally lower-risk products. The TGA has continued to receive a high number of reports of anaphylaxis linked to medicines containing Andrographis, including a fatal case reported in June 2024. A review of the available safety information has determined the risk of severe allergic reactions, including anaphylaxis, associated with Andrographis, cannot be adequately managed within the Listed Medicines framework.

Following the publication of an updated safety review and supplementary report in April 2026, a decision was made to remove Andrographis from the Therapeutic Goods (Permissible Ingredients) Determination (No.2) 2026.

For more information, please refer to High-moderate risk changes to Andrographis 2026.

What should consumers do?

Check the table of products set out below.

Unless otherwise noted:

• If you have any of the below goods, you should not use them.
• You should return the goods to the place of purchase, or contact the Sponsor or supplier (the contact details are in the table).

Further information is also available in the link provided for each recall to our database.

If you have any concerns about a medicine you have been taking, you should talk to a health professional.

Call 000 immediately if you or someone else may be having anaphylaxis.

What is anaphylaxis and what are the risks?

Anaphylaxis is the most severe type of allergic reaction and is a medical emergency.

It requires immediate treatment with adrenaline (epinephrine). Delayed treatment can be life‑threatening.

Andrographis-related anaphylaxis reactions are unpredictable and can happen the first time someone takes it, or after taking it previously without any issue.

Product recalls to date

Reporting problems

Consumers and health professionals are encouraged to report problems with medicines or vaccines. Your report will contribute to our monitoring of these products.

The TGA cannot give advice about an individual's medical condition. You are strongly encouraged to talk with a health professional if you are concerned about a possible adverse event associated with a medicine or vaccine.